On choosing an agent for MTX-IR RA: "(at the end of talk) My short answer could have been... there's no right or wrong. It's still one of the dilemmas we have in the treatment of RA: choosing the right drug for the right patient" - @DanielAletaha #EULAR2021 @RheumNow https://t.co/C45ey1SrA1

@KDAO2011 @UpToDate @TammyTilley @ACRheum @CreakyJoints @UnaMakris @DrDavidKarp @JointMD @ejdein1 @jeffsparks @Janetbirdope @uptoTate @RichardPAConway @MeralElRamahiMD @Yuz6Yusof @AurelieRheumo @Stiddyo @doctorRBC @RheumNow also, and I still remember this from the very first time I met him in person: "Do you know what the most important thing to remember is?" (nervous pause from me) "Have fun. You've gotta have fun!" I still live by this...

I write more about this for @RheumNow - it’s powerful to know that AI can accurately tell the difference between RA, PsA, and healthy controls on the basis of the bony surface at MCP 2: https://t.co/ChDfihnW4f @LkasDer @maier_ak @FAU_Germany OP0145 #EULAR2021 (ping @DrCMcMaster) https://t.co/Pl7yxYfEqr

• Artificial intelligence brings clarity to early bony changes in inflammatory ar…
• https://twitter.com/drdavidliew/status/1400725921208803333

#OP0223 US disease activity and damage score for PsA - ~300 patients from 19 centres - 6 components for disease activity score & 5 for damage -->~90% variability explained --> weighted score -->many sites to scan --> evaluation as BL pred. for MDA #EULAR2021 @RheumNow https://t.co/5kC6YDQi8D

#OP0219 Population based matched medical record database study in PsA vs. non PsA from Israel: -> no differences in mortality -> BL predictors of death -higher risk: higher age, male sex, prior hospitalisation, prior psoriasis, comorbidties -lower: csDMARDs #EULAR2021 #RheumNow

@DanielAletaha @RheumNow In the end the best treatment choice after #MTX insufficient responders not yet clear. Head to head JAK-i vs. non-TNFi interesting Brilliant developing discussion number needed to harm vs. number needed to treat #EULAR2021 @RheumNow

Making decisions session at #EULAR2021 @DanielAletaha When designing for a superiority trial you cannot conclude on non-inferiority. Trials in JAK-i show more or less similar efficacy results to #TNFi Some JAK-i might work better for specific patient #pain #EULAR2021 @RheumNow https://t.co/Bo81nwBFbZ

#OP0220 EuroSpA 17 European registries 17452 bionaive PsA Patients 1999-2018: BL age, disease duration, disease activity decreased 99-18 - disease activity progressively decreased on treatment - At 6M REM rates higher in recent years, 24M REM rates similar #EULAR2021 @RheumNow https://t.co/gZ4tOpRLIf

OP0318 What to consider when tapering DMARDs RETRO – RA pat with DAS<2.6 for >=6months randomised to 3 strategies: remain – taper to 50% - taper then STOP HR for flare 3|4.3 for TAP|STOP Remission depth, disease duration and RF/ACPA as risks to consider #EULAR2021 @RheumNow https://t.co/SR4NDKKrGN

#POS0660 Integrated data analyses of the DARWIN, and FINCH studies (7 in total) on #filgotinib and #statin use: > Around 10% of 4057 RA patients used statins at baseline > Muscle related AE were rare with no clear relation to filgotinib #EULAR2021 @RheumNow

#POS0930 @XBaraliakos investigated baseline predictors differential treatment effect on ASAS20 response at week 12 of 473 ax-PsA using MAXIMISE trial data (#Secukinumab) -> Only nail dystrophy OR: 3 (150mg) OR: 5 (300mg) 🤔But why? #EULAR2021 @RheumNow https://t.co/srb6jGgBqe

#EULAR2021 live might close but there is still on demand until the 4th of July. Interested in my poster: showing that quality of life in at-risk for #RA individuals is reduced but still differ from RA.. have a look at #POS1441 New insights in "pre-disease phase" @RheumNow https://t.co/xtyEgElYkX

What kind of trials would help you in making a decision which DMARD to choose if a patient is not meeting #T2T goal? #EULAR2021 @RheumNow

Norwegian Cardio-Rheuma register review of PsA incidence 32/100,000 pyrs, 28 among 🚹 & 35 among 🚺,highest in 50-59 yo pts. MTX initiated >50% PsA cases w/in 1 yr from index date, 19% used biologic DMARDs w/in 2 yrs. Abstract #POS1041 #EULAR2021 @RheumNow https://t.co/2PGVfeoFV9 https://t.co/CT9WTzcdcc

• https://ard.bmj.com/content/80/Suppl_1/795.2.full

Italian PsABio cohort study: UST ⬆️ overall persistence vs TNFi, especially in females, in monotherapy, BMI <25 or >30 kg/m2, & UST as 2nd-line tx. At 1 year, both UST & TNFi pts showed similar cDAPSA & MDA/VLDA. Abstract #POS1021 #EULAR2021 @RheumNow https://t.co/DGRXmPiTiD https://t.co/s7zMuSBEWt

• https://ard.bmj.com/content/80/Suppl_1/778